Treatment response and survival according to molecular alterations in 229 patients with high-grade gastroenteropancreatic neuroendocrine neoplasms (HG GEP-NEN)

#3486

Introduction: HG GEP-NEN consist of well-differentiated neuroendocrine tumors (NET G3) and poorly differentiated neuroendocrine carcinoma (NEC). The majority have advanced disease, limited treatment options and a poor prognosis.

Aim(s): To find molecular biomarkers predicting treatment efficacy and outcome.

Materials and methods: We sequenced tumor tissue from 229 patients across a panel of 360 cancer-related genes. Clinical data were available through the Nordic Registries. All cases underwent central histopathological review.

Conference:

Presenting Author: Elvebakken H

Authors: Elvebakken H, Venizelos A, Perren A, Couvelard A, Lothe I,

Keywords: neuroendocrine neoplasm, neuroendocrine carcinoma, high-grade, gastroenteropancreatic, molecular alteration, molecular marker,